Showing results (31-40 of 55) with videos related to

Sort By:
Pageof 6
The International Journal of Biological Markers|May 9, 2018
Discordant prostate specific antigen test results despite WHO assay standardizationMartin Boegemann, Christian Arsov, Boris Hadaschik, et al.
Plos One|September 2, 2016
Influence of Statins on Survival Outcome in Patients with Metastatic Castration Resistant Prostate Cancer Treated with Abiraterone AcetateMartin Boegemann, Katrin Schlack, Ann-Kathrin Fischer, et al.
International Journal of Molecular Sciences|February 18, 2017
The Role of the Neutrophil to Lymphocyte Ratio for Survival Outcomes in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with AbirateroneMartin Boegemann, Katrin Schlack, Stefan Thomes, et al.
European Urology Oncology|May 1, 2025
Association of Deep and Durable Prostate-specific Antigen Responses with Outcomes in Metastatic Hormone-sensitive Prostate Cancer: Insights from ARASENS and ARANOTE TrialsChristopher J D Wallis, Sara Ekberg, Alicia K Morgans, et al.
Oncotargets and Therapy|March 24, 2017
Spotlight on atezolizumab and its potential in the treatment of advanced urothelial bladder cancerAhmet Murat Aydin, Solomon L Woldu, Ryan C Hutchinson, et al.
European Urology Oncology|April 9, 2026
Associations Between Quality of Life and Disease Progression in Metastatic Hormone-sensitive Prostate Cancer: Insights from ARASENS and ARANOTE TrialsAlicia K Morgans, Sara Ekberg, Martin Boegemann, et al.
The Prostate|April 4, 2024
Development of a multigenomic liquid biopsy (PROSTest) for prostate cancer in whole bloodIrvin M Modlin, Mark Kidd, Ignat A Drozdov, et al.
European Journal of Cancer (Oxford, England : 1990)|May 25, 2025
Radiological progression-free survival as a surrogate for overall survival in patients with metastatic hormone-sensitive prostate cancer: A bivariate meta-analysisNeal Shore, Alicia K Morgans, Martin Boegemann, et al.
Journal of Comparative Effectiveness Research|January 6, 2026
Population-adjusted network meta-analyses provide new insights into the efficacy of treatment alternatives for metastatic castration-sensitive prostate cancerNeal Shore, Alicia K Morgans, Noman Paracha, et al.
European Journal of Cancer (Oxford, England : 1990)|August 7, 2024
Adjustment for imbalances in baseline characteristics in the MAGNITUDE phase 3 study confirms the clinical benefit of niraparib in combination with abiraterone acetate plus prednisone in patients with metastatic prostate cancerGuilhem Roubaud, Gerhardt Attard, Martin Boegemann, et al.
Pageof 6